BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
← catalyst calendarNCT07778888 · readout ≤ 190 d
Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-21
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2026 | estimated | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dry Eye Disease
Intervention
- Drug: BL1107
Primary outcomes
what the primary-completion date above is the date OFPrimary Part 1: Proportion of participants with complete resolution in conjunctival hyperemia at 30 minutes, in each evaluated concentration of BL1107.
measured Assessed at 30 minutes
Primary Part 2: Proportion of participants with complete resolution in conjunctival hyperemia at 8 hours, in each evaluated concentration of BL1107
measured Assessed at 8 hours
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed